File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus

TitleSafety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus
Authors
KeywordsReferences (29) View In Table Layout
Issue Date1998
PublisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/03009742.asp
Citation
Scandinavian Journal Of Rheumatology, 1998, v. 27 n. 5, p. 342-346 How to Cite?
AbstractIt remains controversial whether administration of exogenous estrogens is safe in systemic lupus erythematosus (SLE). The current study was undertaken to determine the effect of hormone replacement therapy (HRT) on the rate and magnitude of flares in a cohort of postmenopausal SLE patients. Thirty-four patients were prospectively followed. The frequency and severity of disease exacerbations in 11 patients who received HRT was compared with 23 patients who did not receive HRT. Our results showed that both users and non- users of HRT had a comparable age of disease onset, duration of disease, clinical manifestations, and duration of follow-up. No significant increase in the rate (0.12 relapses/patient-year in HRT group vs 0.16 relapses/patient-year in the non-HRT group, p = 0.90) or magnitude (total SLEDAI score increase during flares/patient-year in the HRT and non-HRT groups were 0.55 and 1.22, respectively, p = 0.57) of flares could be demonstrated in patients who received HRT over a median follow-up period of 35 months. We concluded that HRT appeared to be well tolerated and safe in postmenopausal SLE patients. Its potential beneficial effect may outweigh its deleterious effect on disease activity.
Persistent Identifierhttp://hdl.handle.net/10722/91614
ISSN
2015 Impact Factor: 2.307
2015 SCImago Journal Rankings: 1.125
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMok, CCen_HK
dc.contributor.authorLau, CSen_HK
dc.contributor.authorHo, CTKen_HK
dc.contributor.authorLee, KWen_HK
dc.contributor.authorMok, MYen_HK
dc.contributor.authorWong, RWSen_HK
dc.date.accessioned2010-09-17T10:22:13Z-
dc.date.available2010-09-17T10:22:13Z-
dc.date.issued1998en_HK
dc.identifier.citationScandinavian Journal Of Rheumatology, 1998, v. 27 n. 5, p. 342-346en_HK
dc.identifier.issn0300-9742en_HK
dc.identifier.urihttp://hdl.handle.net/10722/91614-
dc.description.abstractIt remains controversial whether administration of exogenous estrogens is safe in systemic lupus erythematosus (SLE). The current study was undertaken to determine the effect of hormone replacement therapy (HRT) on the rate and magnitude of flares in a cohort of postmenopausal SLE patients. Thirty-four patients were prospectively followed. The frequency and severity of disease exacerbations in 11 patients who received HRT was compared with 23 patients who did not receive HRT. Our results showed that both users and non- users of HRT had a comparable age of disease onset, duration of disease, clinical manifestations, and duration of follow-up. No significant increase in the rate (0.12 relapses/patient-year in HRT group vs 0.16 relapses/patient-year in the non-HRT group, p = 0.90) or magnitude (total SLEDAI score increase during flares/patient-year in the HRT and non-HRT groups were 0.55 and 1.22, respectively, p = 0.57) of flares could be demonstrated in patients who received HRT over a median follow-up period of 35 months. We concluded that HRT appeared to be well tolerated and safe in postmenopausal SLE patients. Its potential beneficial effect may outweigh its deleterious effect on disease activity.en_HK
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/03009742.aspen_HK
dc.relation.ispartofScandinavian Journal of Rheumatologyen_HK
dc.subjectReferences (29) View In Table Layouten_HK
dc.subject.meshAdulten_HK
dc.subject.meshCohort Studiesen_HK
dc.subject.meshDisease Progressionen_HK
dc.subject.meshEstrogen Replacement Therapyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLupus Erythematosus, Systemic - complications - physiopathologyen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPostmenopauseen_HK
dc.subject.meshSafetyen_HK
dc.titleSafety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosusen_HK
dc.typeArticleen_HK
dc.identifier.emailLau, CS:cslau@hku.hken_HK
dc.identifier.emailMok, MY:temy@hkucc.hku.hken_HK
dc.identifier.authorityLau, CS=rp01348en_HK
dc.identifier.authorityMok, MY=rp00490en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/03009749850154357en_HK
dc.identifier.pmid9808396-
dc.identifier.scopuseid_2-s2.0-0031784298en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0031784298&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume27en_HK
dc.identifier.issue5en_HK
dc.identifier.spage342en_HK
dc.identifier.epage346en_HK
dc.identifier.isiWOS:000076563200005-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridMok, CC=34668219600en_HK
dc.identifier.scopusauthoridLau, CS=14035682100en_HK
dc.identifier.scopusauthoridHo, CTK=7404652632en_HK
dc.identifier.scopusauthoridLee, KW=35788977700en_HK
dc.identifier.scopusauthoridMok, MY=7006024184en_HK
dc.identifier.scopusauthoridWong, RWS=34875928200en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats